OncRef

Clinical Trial: NCT05925530

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:AstraZeneca
Information Provided By:AstraZeneca
Last Update Posted:2026-09-09

Study Overview

Brief Summary

The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.

Official Title

A Multicentre, Phase II, Single-Arm, Interventional Study of Neoadjuvant Durvalumab and Platinum-based Chemotherapy (CT), Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy (CRT) and Consolidation Durvalumab, in Participants With Resectable or Borderline Resectable Stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

Conditions

Non-small Cell Lung Cancer

Intervention / Treatment

  • Drug: Durvalumab

Other Study ID Numbers

  • D9106C00002
  • 2023-503357-35-00
  • 2023

Start Date (Actual)

2024-02-22

Primary Completion Date (Actual)

2026-01-12

Study Completion Date (Estimated)

2027-08-27

Enrollment (Actual)

142

Study Type

Interventional

Phase

Phase 2